Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
辅助阿贝西利联合内分泌治疗激素受体阳性、人表皮生长因子受体2阴性、高危早期乳腺癌:一项预先计划的monarchE总生存期中期分析的结果,包括5年疗效结果
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.01994
Rastogi, Priya; O'Shaughnessy, Joyce; Martin, Miguel; Boyle, Frances; Cortes, Javier; Rugo, Hope S; Goetz, Matthew P; Hamilton, Erika P; Huang, Chiun-Sheng; Senkus, Elzbieta; Tryakin, Alexey; Cicin, Irfan; Testa, Laura; Neven, Patrick; Huober, Jens; Shao, Zhimin; Wei, Ran; André, Valérie; Munoz, Maria; San Antonio, Belen; Shahir, Ashwin; Harbeck, Nadia; Johnston, Stephen